Intrinsiqq
Abbott Laboratories logo

Abbott Laboratories Insider Trading

ABT

⊜ Compare
Last 12 months

Insiders bought $4.4M and sold $47.5M on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chairman and CEO Robert B Ford sold $46.2M on Aug 25, 43% of their stake, outside a plan.

Net open-market
−$43.1M
5 buys · 10 sales
Under a 10b5-1 plan
0%
of the value sold
Insiders who bought / sold
4 / 7
executives and directors
Last open-market buy
May 2026
May 7, 2026

Get an email when ABT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Sep 2No plan
    John A. McCoy Jr.
    Vice President and Controller · sold 27 at $109.54
    3K
    0.1% of stake
  • Aug 25No plan
    Robert B Ford
    Chairman and CEO · sold 398,832 at avg $115.85
    $46.2M
    43% of stake
  • Aug 11No plan
    Louis H. Morrone
    Executive Vice President · sold 5,850 at $109.83
    643K
    7.6% of stake
  • May 7
    John G Stratton
    Director · bought 2,000 at $86.82
    174K
    9.4% of stake
  • Apr 27
    Daniel J Starks
    Director · bought 10,000 at $92.65
    927K
    0.1% of stake
  • Apr 23
    Philip P Boudreau
    EVP and CFO · bought 2,200 at $91.50
    201K
    2.7% of stake
  • Mar 2No plan
    Elizabeth C. Cushman
    EVP, GC and Secretary · sold 263 at $115.58
    30K
    0.7% of stake
  • Mar 2No plan
    Eric Shroff
    Senior Vice President · sold 709 at $115.58
    82K
    1.8% of stake
  • Mar 2No plan
    Louis H. Morrone
    Executive Vice President · sold 1,144 at $115.58
    132K
    1.5% of stake
  • Mar 2No plan
    Mary K Moreland
    Executive Vice President · sold 613 at $115.58
    71K
    0.5% of stake
  • Mar 2No plan
    John A. McCoy Jr.
    Vice President and Controller · sold 585 at $115.58
    68K
    2.3% of stake
  • Mar 2No plan
    Daniel Gesua Sive Salvadori
    EVP and Group President · sold 885 at $115.58
    102K
    0.6% of stake
  • Feb 4
    Daniel J Starks
    Director · bought 10,000 at avg $108.73
    $1.09M
    0.1% of stake
  • Jan 23
    Robert B Ford
    Chairman and CEO · bought 18,800 at $107.13
    $2.01M
    4.2% of stake
  • Nov 25, 2025No plan
    Eric Shroff
    Senior Vice President · sold 1,586 at $128.02
    203K
    5.0% of stake
  • Aug 8, 2025No plan
    Philip P Boudreau
    EVP and CFO · sold 5,550 at $134.55
    747K
    9.8% of stake
  • Apr 30, 2025No plan
    Sally E. Blount
    Director · sold 2,600 at $129.66
    337K
    7.1% of stake
  • Mar 6, 2025 – Mar 7, 2025No plan
    Lisa D Earnhardt
    EVP and Group President · sold 91,367 at avg $133.83
    $12.2M
    56% of stake
  • Mar 3, 2025No plan
    Andrea F Wainer
    Retired EVP · sold 949 at $138.17
    131K
    1.3% of stake
  • Mar 3, 2025No plan
    Eric Shroff
    Senior Vice President · sold 562 at $138.17
    78K
    1.7% of stake
  • Mar 3, 2025No plan
    Louis H. Morrone
    Executive Vice President · sold 1,111 at $138.17
    154K
    1.6% of stake
  • Mar 3, 2025No plan
    Mary K Moreland
    Executive Vice President · sold 791 at $138.17
    109K
    0.7% of stake
  • Mar 3, 2025No plan
    John A. McCoy Jr.
    Vice President and Controller · sold 562 at $138.17
    78K
    2.6% of stake
  • Feb 5, 2025No plan
    Robert B Ford
    Chairman and CEO · sold 285,388 at $131.17
    $37.4M
    41% of stake
  • Jan 29, 2025 – Jan 30, 2025No plan
    Hubert L Allen
    Executive Vice President · sold 189,788 at avg $128.26
    $24.3M
    51% of stake
  • Jan 30, 2025No plan
    Daniel Gesua Sive Salvadori
    Executive Vice President · sold 23,771 at $128.50
    $3.05M
    16% of stake
  • Jan 28, 2025No plan
    Louis H. Morrone
    Executive Vice President · sold 2,644 at $127.39
    337K
    100% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ABT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ABT

CompareIntrinsic value
BMYBristol-Myers Squibb Company
$64.20+4.04%61
PFEPfizer Inc.
$30.79+2.63%30
ABBVAbbVie Inc.
$294.83+3.09%49
MRKMerck & Co., Inc.
$150.36+3.93%41
UPCUniverse Pharmaceuticals Inc.
$1.47-1.34%39
TEVATeva Pharmaceutical Industries Ltd
$42.13+0.52%46
REGNRegeneron Pharmaceuticals, Inc.
$930.67-4.39%54
VTRSViatris Inc.
$19.22+1.59%24

Held by ETFs

ABT is in 336 US ETFs. The largest of them, with ABT's weight in each:

Spot a number that looks wrong? Check it in ABT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ABT

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.